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Abstract 
Valvular heart diseases (VHD) increase the risk of cardiovascular morbidity and mortality. 
Little is known about correlation between circadian blood pressure profile and VHD. The aim 
of the study was to clarify the association of dipping status and VHD prevalence.  
103 consecutive patients (male: 50.5%), who underwent 24-hour ambulatory BP measurement 
and ECG-Holter simultaneously were analysed. We divided patients into 3 groups: dipping 
was defined as 10–20% (28.2%), non-dipping as  <  10% (50.5%) fall in nocturnal BP and 
reverse-dipping as higher nocturnal than diurnal BP (21.4%).  VHD was assessed by 
transthoracic echocardiography and described as mild, moderate or severe regurgitation or 
stenosis accordingly. Further we compared severity of VHD, nocturnal fall pattern and ABPM 
features in all groups.  
We found no statistically significant associations between dipping pattern and frequency of 
VHD. We also found no statistical association between dipping status and severity of VHD. 
Our study showed some correlations between VHD severity and different ABPM parameters.  
Though dipping status obtained by ABPM did not influence severity of VHD, there were 
associations between ABPM outcomes and VHD. This finding may have important 
implications on care of patients with hypertension and VHD, though further studies are 
needed. 
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Introduction 
Hypertension is a growing problem, and currently, there are over 1 billion hypertensive 
individuals worldwide ]. In 1978 Millar-Craig et al. described circadian variation of blood 
 pressure (BP) using continuous intra-arterial monitoring [3]. Nowadays ambulatory blood 
pressure measurement (ABPM) is a noninvasive method to obtain circadian blood pressure 
profile (CBPP) [4].   
Studies prove that non-dipping pattern in hypertensive individuals might be associated 
with increased cardiovascular risk [5–7]. The lower or lack of fall in nocturnal BP values 
could also cause target organ damage. Literature brings evidence that non-dipping pressure 
profile is connected with left ventricle hypertrophy (LVH), cardiac functional alteration, renal 
damage, carotid artery abnormalities and cerebrovascular diseases [8–15] . Valvular heart 
disease (VHD) may be not as common as coronary artery disease (CAD) or heart failure , but 
remains significant, since it frequently requires interventions [16, 17]. The aim of the study 
was to assess if there are associations between VHD prevalence as well as occurrence and 
either CBPP or ABPM parameters. 
 
Materials and methods 
Study population 
This was a retrospective study analyzing data of 103 patients hospitalized in the Department 
of Cardiology and Hypertension in Central Research Hospital of the Ministry of Interior and 
Administration in Warsaw between January 2012 and December 2013. All consecutive 
patients, who simultaneously underwent ABPM and 24-hours ECG Holter (ECG-Holter), 
were included in further analysis. According to nocturnal fall pattern we divided patients into 
three groups. Dipping was defined as a 10–20% fall in nocturnal systolic BP (SBP), non-
dipping as less than 10%, and reverse-dipping as higher average SBP during the night than 
during the day [6, 18]. Collected data were analyzed retrospectively and Local Ethics 
Committee gave consent to conduct the trial. 
 
Measurements 
In the study Treacker NIBP2 SpaceLabs Healthcare and ABP 90217-7Q SpaceLabs 
Healthcare devices were used to obtain ABPM and Lifecard CF Reynolds Medical device to 
assess ECG-Holter. Measurements of BP were performed every 10 minutes during awake 
hours and every 30 minutes at night. Additionally, all patients had 
transthoracic echocardiography (TTE) using Phillips IE-33 and EPIQ Ultrasound machines 
and rest-ECG performed. In TTE VHD severity was described as none (0), mild (+), moderate 
(++) or severe (+++). 
 
 Statistics 
Statistical analysis was performed on R version 3.1.2 [19]. Continuous variables are presented 
as number of observations and mean with standard deviation; categorical variables are 
reported as frequencies and percentages. The distribution of continuous variables was first 
analysed with Shapiro-Wilk test of normality and then according to the results ANOVA test 
or Kruskal-Wallis test were used. Categorical variables were compared using Fisher's exact 
test. The significance level was set at 0.05. 
 
Results 
One hundred three consecutive patients (male: 50.5%) with mean age 63.9 ( ±  17.7) years 
simultaneously underwent ABPM and ECG-Holter were included in further analysis. 
According to ABPM outcomes 29 (28%) patients were dippers, 52 (50%) were non-dippers 
and 22 (21%) were reverse-dippers respectively. The reverse dipper group was the oldest, 
with mean age 74.9  ±  10.9 years, and differences in age between groups were statistically 
significant (p  <  0.001). Study population characteristic is presented in Table 1. There were 
significant differences between groups in occurrence of diagnosis of chronic kidney disease 
(CKD) and peripheral artery disease (PAD), with the higher prevalence of those diseases in 
non–dipper and the highest in reverse-dipper group. Mean systolic and diastolic pressure, both 
diurnal and nocturnal, which differed statistically significantly between subgroups in our 
study population, is presented also in Table 1.  
Echocardiography parameters assessed in our study population are given in Table 2. 
From those results only left atrium diameter (LAD) differed significantly regarding CBPP 
(40.2  ±  4.8 mm; 43.8  ±  6.2 mm; 41.8  ±  5.2 mm; p  =  0.026; dippers, non-dippers, reverse-
dippers, respectively). We found no statistically significant difference between neither 
prevalence nor occurrence of VHD regarding CBPP in our study population. Parameters are 
given in Table 2 and Table 3.  
List of drugs administered in our study population is given in Table 4. Both: β- and α-
adrenolytics were more commonly used in non-dipper and reverse-dipper than in dipper 
population (α-adrenolytics: 0%; 13.04%; 30%; p  =  0.009; β-adrenolytics: 57.69%; 69.57%; 
95%; p  =  0.011; dippers, non-dippers, reverse dippers, respectively). There were no 
statistically significant differences in drugs doses (Table 5). 
Our study showed that severity of aortic stenosis (AS) correlated positively with 
maximal nocturnal systolic blood pressure (SBP) (ρ  =  0.208; p  =  0.038) and that severity of 
aortic regurgitation (AR) correlated negatively with diastolic blood pressure (DBP) during the 
 nighttime (ρ  =  -0.214; p  =  0.033). Additionally we found that severity of AR was 
connected with lower maximal heart rate (HR) at night (ρ  =  -0.197; p  =  0.050), while AS 
correlated with lower maximal HR during awake hours (ρ  =  -0.202; p  =  0.044). Tricuspid 
stenosis correlated negatively with both awake (ρ  =  -0.199; p  =  0.047) and nightly DBP (ρ  
=  -0.207; p  =  0.039) and with maximal DBP during awake hours (ρ  =  -0.198; p  =  0.048). 
During awake hours both minimal SBP (ρ  =  -0.197; p  =  0.050) and maximal DBP (ρ  =  -
0.236; p  =  0.018) correlated negatively with pulmonary regurgitation. 
 
Discussion 
Heart is one of the organs damaged by hypertension. Some authors described LVH and higher 
left ventricle mass index (LVMI) in non-dipper patients group compared to dippers [8, 20–
22]. Those data are inconclusive, because others failed to prove those outcomes [23–25]. It 
may be due to different methods used in those studies, i.e. Cuspidi et al., who proved 
statistically significant differences in LVH prevalence and higher LVMI in never-treated non-
dippers with reproducible non-dipper pattern of hypertension comparing to those with 
reproducible dipper pattern of hypertension, used multiple ABPM measurements in order to 
divide patients into groups, while others used only 1 measurement [8]. Cuspidi et al. [9] 
described that fact as the reason of different outcomes in comparison with other studies. This 
fact may be relevant, but other authors reported high reproducibility of ABPM outcomes 
regarding CBPP in their study population (hemodialysis patients) after 6 and 12 months [20]. 
Ferrara et al. [26] reported that differences in echocardiography outcomes may be significant 
in dippers comparing to non-dippers only in recently discovered hypertension and showed 
similar changes in both groups in long-standing hypertension. Additionally, Sokmen et al. 
[27] found that there was no statistically significant difference between dippers and non-
dippers hypertensive patients, who had adequate BP control regarding LVH, LVMI. We also 
assessed presence of LVH and in our population we found that non-dippers had higher both 
posterior wall end-diastolic diameter (PWDd) and interventricular septal end-diastolic 
dimension (IVSd). Additionally, we found that there was an inverse tendency in reverse-
dipper group, what was in contra position to Wang et al. [28] results. Although, in all those 
parameters we did not reach statistical significance, what might be due to relatively smaller 
study population than in cited studies. Additionally, in another original article recently 
submitted for publication, we analyzed factors determining CBPP and nightly fall of SBP. We 
found that patients who were older, diagnosed with peripheral artery disease or dilated 
cardiomyopathy and who used α-adrenolytics had lower fall in nocturnal SBP. Also, we found 
 that patients who had lower hemoglobin concentration, higher CK-MB values or lower 
maximal heart rate had lower fall in nocturnal SBP. We assessed higher prevalence of altered 
CBPP in patients who used β- or α-adrenolytics or torasemide. Though according to our 
results none of TTE parameters (including LVH) determined CBPP and nightly fall of SBP. 
Looking further into analysis of TTE measurements, in the context of CBPP larger LAD, was 
already described by others in non-dipper group [9]. Our results proved those outcomes 
regarding differences between dippers and non-dippers. Surprisingly we found that this 
tendency was not continued in reverse-dipper group, although we found no studies to compare 
our outcomes with. Regarding detailed analysis of VHD in the context of CBPP we found 
only one study in which authors assessed VHD (in that particular study only aortic valve 
disease was considered) influence on CBPP. Authors found that aortic valve disease was 
connected with altered CBPP. Our outcomes did not prove that fact. It may be due to smaller 
population in the cited Jensen et al. study (13 patients with either aortic regurgitation or aortic 
stenosis) [29] . 
Above-mentioned Jensen’s study may also be considered as one of the reasons why 
there was a correlation between AS severity and higher maximal SBP at night. They found 
that there was higher activity of renin-angiotensin system in patients with aortic valve disease 
[29]. Others described higher sympathetic nervous system activity in patients diagnosed with 
AS [30]. Further studies are needed, because our outcomes regarding other correlations were 
not proved by other studies.  
As we already mentioned, limitation of our study may be the fact that we used only 
one ABPM outcome in order to define and divide our study population. Additionally 
relatively large reverse dipper population may be considered both, limitation and strength of 
our study. It could be limitation, because there are not enough data regarding reverse dipper 
population in literature, so we had little opportunity to compare our results. It may be 
considered strength because it gives information about population, which has not been 
precisely described so far.  
 
Conclusion 
To conclude, we found influence of neither occurrence nor severity of VHD on CBPP 
in our study population. Though we found some interesting associations between ABPM 
parameters and severity of VHD. Further studies are needed, but these outcomes may have 
implications on care on patients with hypertension. 
 
 Konflikt interesów  
Autorzy nie zgłaszają konfliktu interesów 
Streszczenie 
Wady zastawkowe serca (z ang. valvular heart disease — VHD) zwiększają ryzyko 
zachorowań i zgonów z przyczyn sercowo-naczyniowych. Niewiele jest wiadomo na temat 
zależności pomiędzy profilem dobowym ciśnienia tętniczego (z ang. circadian blood pressure 
profile), a VHD. Celem tej pracy było wyjaśnienie związku pomiędzy CBPP, a VHD.  
103 kolejnych pacjentów (mężczyźni: 50,5%), którzy wykonany mieli równocześnie 
całodobowy pomiar ciśnienia tętniczego i 24-godzinny zapis EKG metodą Holtera byli 
włączeni do badania. Podzielono pacjentów na 3 grupy: „dippers” zdefiniowani zostali jako 
osoby mające ciśnienie tętnicze w nocy o 10–20% niższe niż w ciągu dnia (28,2%), „non-
dippers” jako osoby mające spadek ciśnienia tętniczego w nocy mniejszy niż 10% (50,5%), 
natomiast „reverse-dippers” stanowily osoby mające wyższe wartości ciśnienia w nocy, niż w 
ciągu dnia (21,4%). VHD oceniana była przy pomocy echokardiografii przezklatkowej i 
oceniana jako mała, umiarkowana lub ciężka. Następnie porównywano ciężkość VHD, CBPP 
i dane z całodobowego pomiaru ciśnienia tętniczego we wszystkic grupach. 
Nie znaleziono istotnej statystycznie zależności pomiędzy CBPP i częstością występowania 
VHD. Co więcej, nie znaleziono również istotnej statystycznie zależności pomiędzy CBPP, a 
ciężkością VHD. Znaleziono korelację pomiędzy ciężkością VHD, a niektórymi parametrami 
ocenianymi w trakcie całodobowego pomiaru ciśnienia tętniczego.  
Pomimo, że CBPP nie wpływał na ciężkość VHD istnieją zależności pomiędzy wynikami 
całodobowego pomiaru ciśnienia tętniczego i VHD. Dalsze badania są konieczne. 
Słowa kluczowe: rytm okołodobowy; nadciśnienie tętnicze; wady zastawkowe serca 
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Table 1. Population characteristics  
 Dipper Non–dipper Reverse dipper  
Age [years] 55.24  ±  17.83 63.98  ±  17.46 74.91  ±  10.86 p < 0.001 
Gender [M/F] 16/13 30/22 6/16 p = 0.052 
 SBP day [mmHg] 129.72  ±  11.30 127.48  ±  13.81 125.77  ±  15.32 p = 0.575 
SBP night 
[mmHg] 
111.55  ±  9.16 
121.58  ±  13.73 133.00  ±  18.04 p < 0.001 
SBP fall 13.93  ±  2.83 4.63  ±  2.91 -5.61  ±  3.71 p < 0.001 
DBP day [mmHg] 74.41  ±  8.19 71.23  ±  8.67 67.45  ±  6.53 p = 0.009 
DBP night 
[mmHg] 
61.34  ±  6.67 65.29  ±  7.87 67.86  ±  8.05 p = 0.009 
DBP fall 17.46  ±  3.93 8.21  ±  5.32 -0.53  ±  5.35 p < 0.001 
HF 8 (27.59%) 17 (32.69%) 11 (52.38%) p = 0.188 
HF-REF 0 (0.00%) 1 (1.92%) 0 (0.00%) p > 0.999 
HF-PEF 6 (20.69%) 15 (28.85%) 10 (47.62%) p = 0.126 
CKD 1 (3.70%) 9 (17.65%) 6 (30.00%) p = 0.045 
PAD 1 (4.00%) 3 (5.88%) 5 (26.32%) p = 0.031 
DCM 0 (0.00%) 2 (3.85%) 2 (10.00%) p = 0.175 
CAD  6 (20.69%) 8 (15.38%) 7 (35.00%) p = 0.178 
Post MI 2 (7.14%) 2 (3.85%) 3 (15.79%) p = 0.212 
Post CABG 0 (0.00%) 0 (0.00%) 1 (5.26%) p = 0.192 
OSAS 7 (25.00%) 13 (25.00%) 2 (9.09%) p = 0.302 
DM 4 (14.29%) 7 (13.73%) 2 (10.00%) p > 0.999 
Hyperlipidemia  14 (50.00%) 30 (57.69%) 13 (61.90%) p = 0.720 
COPD 0 (0.00%) 0 (0.00%) 1 (5.00%) p = 0.213 
AF 3 (10.34%) 15 (29.41%) 8 (36.36%) p = 0.055 
NT-proBNP 
[pg/mL] 
332.40  ±  
359.33 
1490.38  ±  
2507.92 
1414.30  ±  
2919.21 
p = 0.650 
CK [µg/L] 109.56  ±  38.57 92.66  ±  49.09 119.62  ±  65.23 p = 0.103 
CK–MB [µg/L] 16.56  ±  5.09 18.75  ±  9.88 24.82  ±  16.82 p = 0.030 
AF — Atrial Fibrillation; CAD — Coronary Artery Disease; CK — creatine kinase; CK—
MB — CK MB isoenzyme; CKD — Chronic Kidney Disease; COPD — Chronic Obstructive 
Pulmonary Disease; DBP — Diastolic Blood Pressure; DCM — Dilated Cardiomyopathy; 
DM — Diabetes Mellitus; HF — Heart Failure; HF—PEF — HF with Preserved Ejection 
Fraction; HF—REF — HF with Reduced Ejection Fraction; NT-proBNP — N-terminal of the 
prohormone brain natriuretic peptide; OSAS — Obstructive Sleep Apnea Syndrome; p — 
overall p-value for 3-group comparison of means (ANOVA test) or distributions (Kruskal-
Wallis test) for continuous variables and percentages (χ2 test) for categorical variables; PAD 
 — Peripheral Artery Disease; Post CABG — Post Coronary Artery Bypass Graft; Post MI — 
Post Myocardial Infarction; SBP — Systolic Blood Pressure. 
 
Table 2. Echocardiography parameters 
 Dipper Non–dipper Reverse dipper  
EF [%] 62.39  ±  4.69 61.35  ±  7.23 59.86  ±  6.23 p = 0.127 
LVDd [mm] 50.31  ±  4.43 50.18  ±  5.88 50.10 ± 5.94 p = 0.700 
RVDd [mm] 31.50 ± 4.53 32.73 ± 4.86 31.45 ± 6.11 p = 0.475 
LAD [mm] 40.21 ± 4.80 43.75 ± 6.15 41.76 ± 5.22 p = 0.026 
IVSd [mm] 10.59 ± 1.21 10.94 ± 1.77 10.11 ± 3.00 p = 0.676 
PWDd [mm] 10.34 ± 1.34 10.76 ± 1.73 10.14 ± 1.53 p = 0.260 
TAPSE 
[mm] 
22.00 ± 4.24 23.00 ± 5.89 21.83 ± 2.99 p = 0.901 
IVC [mm] 16.00 ± 4.58 20.50 ± 5.45 15.46 ± 7.98 p = 0.663 
VHD:     
AR 7 (25.00%) 18 (35.29%) 6 (28.57%) p = 0.632 
AS 0 (0.00%) 2 (3.92%) 0 (0.00%) p = 0.717 
MR 20 (68.97%) 36 (70.59%) 18 (85.71%) p = 0.370 
MS 0 (0.00%) 0 (0.00%) 0 (0.00%) NA 
TR 10 (35.71%) 28 (54.90%) 12 (57.14%) p = 0.236 
TS 0 (0.00%) 2 (3.92%) 0 (0.00%) p = 0.712 
PR 0 (0.00%) 1 (1.96%) 1 (4.76%) p = 0.454 
PS 0 (0.00%) 0 (0.00%) 0 (0.00%) NA 
AR — aortic regurgitation; AS — aortic stenosis; ; EF — ejection fraction; IVC — inferior 
vena cava; IVSd— intraventricular septum end-diastolic diameter; LAD — left atrium 
diameter; LVDd — left ventricle end diastolic dimension; MR — mitral regurgitation; MS — 
mitral stenosis; p — overall p-value for 3-group comparison of means (ANOVA test) or 
distributions (Kruskal-Wallis test) for continuous variables and percentages (χ2 test) for 
categorical variables; PR — pulmonary regurgitation; PS — pulmonary stenosis; PWDd — 
posterior wall end-diastolic diameter; RVDd — right ventricle end diastolic dimension; 
TAPSE — tricuspid annular plane systolic excursion; TR — tricuspid regurgitation; TS — 
tricuspid stenosis; VHD — valvular heart disease. 
 
Table 3. Valvular heart disease severity. 
 
Severity Dipper Non-dipper Reverse dipper 
 
AR 0 21 (75.00%) 33 (64.71%) 15 (71.43%) p  = 0.869 
 1 7 (25.00%) 17 (33.33%) 6 (28.57%)  
 2 0 (0.00%) 1 (1.96%) 0 (0.00%)  
AS 0 28 (100.00%) 49 (96.08%) 21 (100.00%) p > 0.999 
  
Severity Dipper Non-dipper Reverse dipper 
 
 1 0 (0.00%) 1 (1.96%) 0 (0.00%)  
 3 0 (0.00%) 1 (1.96%) 0 (0.00%)  
MR 0 9 (31.03%) 15 (29.41%) 3 (14.29%) p = 0.422 
 1 19 (65.52%) 28 (54.9%) 15 (71.43%)  
 2 1 (3.45%) 7 (13.73%) 2 (9.52%)  
 3 0 (0.00%) 1 (1.96%) 1 (4.76%)  
TS 0 28 (100.00%) 49 (96.08%) 21 (100.00%) p = 0.712 
 1 0 (0.00%) 2 (3.92%) 0 (0.00%)  
TR 0 18 (64.29%) 23 (45.10%) 9 (42.86%) p = 0.280 
 1 10 (35.71%) 23 (45.10%) 10 (47.62%)  
 2 0 (0.00%) 5 (9.80%) 2 (9.52%)  
PR 0 28 (100.00%) 50 (98.04%) 20 (95.24%) p = 0.454 
 1 0 (0.00%) 1 (1.96%) 1 (4.76%)  
 
AR — aortic regurgitation; AS — aortic stenosis; MR — mitral regurgitation; p — overall p-
value for 3-group comparison of percentages (χ2 test) for categorical variables; PR — 
pulmonary regurgitation; TR — tricuspid regurgitation; TS — tricuspid stenosis. 
 
Table 4. Drugs administered in study population 
 Dipper Non–dipper Reverse dipper  
β-adrenolytics  15 (57.69%) 32 (69.57%) 19 (95.00%) p = 0.011 
α-adrenolytics 0 (0.00%) 6 (13.04%) 6 (30.00%) p = 0.009 
Ca-antagonists 9 (34.62%) 26 (56.52%) 9 (45.00%) p = 0.196 
ACE–i 16 (61.54%) 22 (47.83%) 13 (65.00%) p = 0.388 
ARB 3 (11.54%) 14 (30.43%) 6 (30.00%) p = 0.164 
Amiodarone 0 (0.00%) 1 (2.17%) 0 (0.00%) p > 0.999 
Digoxine 0 (0.00%) 2 (4.35%) 0 (0.00%) p = 0.714 
Aldosterone 
antagonists 
0 (0.00%) 7 (15.22%) 1 (5.00%) p = 0.073 
Furosemide  0 (0.00%) 8 (17.39%) 2 (10.00%) p = 0.057 
Torasemide 1 (3.85%) 2 (4.35%) 7 (35.00%) p = 0.002 
Kaldyum 0 (0.00%) 6 (13.04%) 0 (0.00%) p = 0.047 
 Kalipoz 4 (15.38%) 19 (41.3%) 12 (60.00%) p = 0.006 
Hydrochlorotiazide 1 (3.85%) 8 (17.02%) 0 (0.00%) p = 0.065 
Indapamide 5 (19.23%) 9 (19.57%) 3 (15.00%) p = 0.941 
ASA 7 (26.92%) 12 (26.09%) 8 (40.00%) p = 0.524 
VKA 3 (11.54%) 10 (21.74%) 3 (15.00%) p = 0.593 
LMWH 0 (0.00%) 1 (2.17%) 1 (5.00%) p = 0.467 
Statin 18 (69.23%) 30 (65.22%) 15 (75.00%) p = 0.732 
ACE-i — Angiotensin-Converting-Enzyme inhibitor; ARB — Angiotensin II receptor 
blocker; ASA — Acetylsalicylic Acid; LMWH — Low-Molecular-Weight Heparin; p — 
overall p-value for 3-group comparison of percentages (χ2 test) for categorical variables; 
VKA — Vitamin K Antagonist. 
 
Table 5. Drugs doses in study population 
 Doses Dipper Non–dipper Reverse dipper  
β-adrenolytics  0 11 (44.00%) 14 (31.11%) 1 (5.26%) p = 0.082 
 1 9 (36.00%) 22 (48.89%) 12 (63.16%)  
 2 5 (20.00%) 7 (15.56%) 5 (26.32%)  
 3 0 (0.00%) 2 (4.44%) 1 (5.26%)  
ACE-i 0 10 (38.46%) 24 (52.17%) 7 (35.00%) p = 0.073 
 1 0 (0.00%) 5 (10.87%) 3 (15.00%)  
 2 6 (23.08%) 2 (4.35%) 4 (20.00%)  
 3 10 (38.46%) 15 (32.61%) 6 (30.00%)  
ARB 0 23 (88.46%) 32 (71.11%) 14 (70.00%) p = 0.612 
 1 1 (3.85%) 2 (4.44%) 1 (5.00%)  
 2 2 (7.69%) 7 (15.56%) 3 (15.00%)  
 3 0 (0.00%) 4 (8.89%) 2 (10.00%)  
1 — small doses; 2 — medium doses; 3 — high doses; ACE-i — Angiotensin-Converting-
Enzyme inhibitor; ARB — Angiotensin II receptor blocker; p — overall p-value for 3-group 
comparison of percentages (χ2 test) for categorical variables. 
 
